Subrata Ghosh

46.3k total citations · 11 hit papers
590 papers, 31.0k citations indexed

About

Subrata Ghosh is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Subrata Ghosh has authored 590 papers receiving a total of 31.0k indexed citations (citations by other indexed papers that have themselves been cited), including 358 papers in Genetics, 258 papers in Epidemiology and 199 papers in Surgery. Recurrent topics in Subrata Ghosh's work include Inflammatory Bowel Disease (347 papers), Microscopic Colitis (209 papers) and Eosinophilic Esophagitis (56 papers). Subrata Ghosh is often cited by papers focused on Inflammatory Bowel Disease (347 papers), Microscopic Colitis (209 papers) and Eosinophilic Esophagitis (56 papers). Subrata Ghosh collaborates with scholars based in United Kingdom, Canada and United States. Subrata Ghosh's co-authors include Remo Panaccione, Gilaad G. Kaplan, Eric I. Benchimol, Herman W. Barkema, Siew C. Ng, Marietta Iacucci, Natalie A. Molodecky, Greg Chernoff, Mollie Ferris and Fox E. Underwood and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Subrata Ghosh

570 papers receiving 30.3k citations

Hit Papers

Worldwide incidence and p... 2003 2026 2010 2018 2017 2011 2012 2013 2020 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
    2017 4.3k citations Remo Panaccione, Subrata Ghosh et al. profile →
  2. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
    2011 3.7k citations Remo Panaccione, Subrata Ghosh et al. profile →
  3. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
    2012 838 citations William J. Sandborn, Christopher Gasink et al. profile →
  4. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
    2013 685 citations Remo Panaccione, Subrata Ghosh et al. profile →
  5. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
    2020 681 citations Ren Mao, Marietta Iacucci et al. profile →
  6. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
    2013 632 citations Remo Panaccione, Subrata Ghosh et al. profile →
  7. Natalizumab for Active Crohn's Disease
    2003 615 citations Subrata Ghosh et al. profile →
  8. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
    2016 360 citations William J. Sandborn, Brian G. Feagan et al. profile →
  9. The Global Incidence of Appendicitis
    2017 352 citations Subrata Ghosh, Gilaad G. Kaplan et al. profile →
  10. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
    2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →
  11. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
    2020 207 citations William J. Sandborn, Subrata Ghosh et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Subrata Ghosh 17.1k 12.2k 8.5k 5.9k 5.1k 590 31.0k
Gilaad G. Kaplan 15.7k 0.9× 13.3k 1.1× 11.2k 1.3× 4.5k 0.8× 6.2k 1.2× 486 34.2k
Richard N. Fedorak 15.4k 0.9× 11.8k 1.0× 6.7k 0.8× 5.4k 0.9× 4.3k 0.9× 393 27.2k
Remo Panaccione 26.4k 1.5× 19.4k 1.6× 10.1k 1.2× 8.2k 1.4× 4.4k 0.9× 704 36.7k
Toshifumi Hibi∥ 9.9k 0.6× 8.3k 0.7× 7.6k 0.9× 7.1k 1.2× 5.3k 1.0× 788 26.6k
Gerhard Rogler 11.0k 0.6× 7.6k 0.6× 6.9k 0.8× 5.6k 0.9× 7.7k 1.5× 645 26.9k
Gert Van Assche 26.9k 1.6× 20.6k 1.7× 10.7k 1.3× 8.9k 1.5× 3.2k 0.6× 476 36.8k
Bruce E. Sands 28.6k 1.7× 20.9k 1.7× 10.8k 1.3× 9.9k 1.7× 4.5k 0.9× 596 39.6k
María T. Abreu 10.1k 0.6× 7.3k 0.6× 5.0k 0.6× 6.4k 1.1× 4.8k 0.9× 378 21.4k
Ashwin N. Ananthakrishnan 11.6k 0.7× 10.6k 0.9× 5.8k 0.7× 2.4k 0.4× 4.4k 0.9× 498 22.5k
Anne M. Griffiths 16.1k 0.9× 11.3k 0.9× 7.3k 0.9× 3.6k 0.6× 2.6k 0.5× 363 23.0k

Countries citing papers authored by Subrata Ghosh

Since Specialization
Citations

This map shows the geographic impact of Subrata Ghosh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Subrata Ghosh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Subrata Ghosh more than expected).

Fields of papers citing papers by Subrata Ghosh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Subrata Ghosh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Subrata Ghosh. The network helps show where Subrata Ghosh may publish in the future.

Co-authorship network of co-authors of Subrata Ghosh

This figure shows the co-authorship network connecting the top 25 collaborators of Subrata Ghosh. A scholar is included among the top collaborators of Subrata Ghosh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Subrata Ghosh. Subrata Ghosh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santacroce, Giovanni, Irene Zammarchi, Olga Maria Nardone, et al.. (2025). Rediscovering histology – the application of artificial intelligence in inflammatory bowel disease histologic assessment. Therapeutic Advances in Gastroenterology. 18. 1128508501–1128508501. 4 indexed citations
2.
Feagan, Brian G., Stephen B. Hanauer, Séverine Vermeire, et al.. (2024). Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn’s Disease. Digestive Diseases and Sciences. 69(6). 2044–2054. 4 indexed citations
3.
Ghosh, Subrata, et al.. (2024). Impact of local navigation rules on biased random walks in multiplex Markov chains. Physica A Statistical Mechanics and its Applications. 654. 130122–130122.
4.
Flood, Peter F., et al.. (2024). T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch. Autoimmunity Reviews. 24(3). 103735–103735. 5 indexed citations
5.
Santacroce, Giovanni, Rocío del Amor, Andrea Buda, et al.. (2024). Simultaneous Detection and Conversion Among Endoscopic Enhancement Modalities. 1–4. 1 indexed citations
6.
Santacroce, Giovanni, Irene Zammarchi, Rocío del Amor, et al.. (2024). Inflammation Detection Using Ensemble Endoscopic Multimodal Assessment in Inflammatory Bowel Disease. Lirias (KU Leuven). 1–4. 1 indexed citations
7.
Travis, Simon, Tadakazu Hisamatsu, Monika Fischer, et al.. (2024). OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial. Journal of Crohn s and Colitis. 18(Supplement_1). i21–i23. 5 indexed citations
8.
Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.
9.
Ghosh, Subrata, Brian G. Feagan, Elyssa Ott, et al.. (2024). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis. Journal of Crohn s and Colitis. 18(7). 1091–1101. 17 indexed citations
10.
11.
He, Yiming, Ren Mao, Gang Yuan, et al.. (2022). The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. Therapeutic Advances in Gastroenterology. 15. 1098285283–1098285283. 10 indexed citations
12.
Sandborn, William J., P. Rutgeerts, C Gasink, et al.. (2018). Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary Pharmacology & Therapeutics. 48(1). 65–77. 115 indexed citations
13.
Sands, Bruce E., Christopher Gasink, Lizhen Gao, et al.. (2017). OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study. HighWire Press Open Archive. A23.1–A23. 6 indexed citations
14.
Seow, Cynthia H., Yvette Leung, Niels Vande Casteele, et al.. (2017). The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 45(10). 1329–1338. 61 indexed citations
15.
Ma, Christopher, Richard N. Fedorak, Gilaad G. Kaplan, et al.. (2017). Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology & Therapeutics. 45(9). 1232–1243. 123 indexed citations
16.
Colombel, Jean‐Frédéric, William J. Sandborn, Walter Reinisch, et al.. (2017). Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology & Therapeutics. 47(2). 219–228. 32 indexed citations
17.
Hirota, Simon A., Aito Ueno, Helen M. Becker, et al.. (2016). Exaggerated IL-15 and Altered Expression of foxp3+ Cell-Derived Cytokines Contribute to Enhanced Colitis in Nlrp3−/− Mice. Mediators of Inflammation. 2016. 1–12. 3 indexed citations
18.
Gasia, Miriam Fort, Remo Panaccione, Gilaad G. Kaplan, et al.. (2015). P175. Clinical outcome of ulcerative colitis with mucosal healing demonstrated by white light endoscopy but with subtle abnormalities detected by high definition iSCAN endoscopy. Journal of Crohn s and Colitis. 9(suppl 1). S164–S164. 1 indexed citations
19.
Ramachandran, Rithwik, Eric Hyun, Liena Zhao, et al.. (2013). TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proceedings of the National Academy of Sciences. 110(18). 7476–7481. 141 indexed citations
20.
Ghosh, Subrata, Pilhan Kim, Xiaoan Zhang, et al.. (2010). A Novel Imaging Approach for Early Detection of Prostate Cancer Based on Endogenous Zinc Sensing. Cancer Research. 70(15). 6119–6127. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gilaad G. Kaplan Breakdown of academic impact, for papers by Richard N. Fedorak Breakdown of academic impact, for papers by Remo Panaccione Breakdown of academic impact, for papers by Toshifumi Hibi∥ Breakdown of academic impact, for papers by Gerhard Rogler Breakdown of academic impact, for papers by Gert Van Assche Breakdown of academic impact, for papers by Bruce E. Sands Breakdown of academic impact, for papers by María T. Abreu Breakdown of academic impact, for papers by Ashwin N. Ananthakrishnan Breakdown of academic impact, for papers by Anne M. Griffiths
Rankless by CCL
2026